Gilead Stock News

Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More

Global Small Molecule Sterile Injectable Drugs Market Overview: A brilliant Small Molecule Sterile Injectable Drugs Market research report brings into focus the key market dynamics of the sector. This market study also analyzes the market status, market share, growth rate, future

If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill.

Hixon Zuercher LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 15,862 shares of the biopharmaceutical company’s stock after acquiring an additional 287 shares during the period. Hixon Zuercher LLC’s holdings in Gilead Sciences were worth $1,108,000 as of its […]

The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.

Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players

Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV i

The European Commission has approved Gilead Sciences Inc''s (NASDAQ: GILD ) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (TNBC). The approval for the antibody-drug conjugate covers adult patients with unresectable or metastatic TNBC who have received two or more Full story available on Benzinga.com

Gilead, like every other US-based biopharmaceutical company, is set to see long-term margin contraction once or if government programs like Medicare and Medicaid are allowed to negotiate drug prices.

If approved, Bulevirtide will be the first treatment option for adult patients in the US with chronic Hepatitis Delta Virus infection with compensated liver disease The post Gilead submits Biologics Licence Application to USFDA for Bulevirtide appeared first on Express Pharma .

N.E.W. Advisory Services LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,909 shares of the biopharmaceutical companys stock after buying an additional 817 shares during the quarter. N.E.W. []

Greylin Investment Mangement Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% during the third quarter, Holdings Channel reports. The institutional investor owned 187,740 shares of the biopharmaceutical companys stock after buying an additional 1,630 shares during the period. Gilead Sciences comprises approximately 2.7% of Greylin Investment Mangement Inc.s investment portfolio, making the []

Shares of Gilead Sciences, Inc. (GILD) closed 1. The post Gilead Submits Biologics License Application for Bulevirtide; Shares Rise appeared first on Smarter Analyst .

Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.